Download PDF
Hamostaseologie 1984; 04(03): 91-97
DOI: 10.1055/s-0038-1659976
Originaler Artikel
Schattauer GmbH

Fibrinolyse und Kalzium

F. Haverkate
1   Gaubius-Institut, TNO, Leiden, Niederlande
,
W. Nieuwenhuizen
1   Gaubius-Institut, TNO, Leiden, Niederlande
› Author Affiliations
Further Information

Publication History

Publication Date:
22 June 2018 (online)

Also available at
    Permissions and Reprints

 

 

  • LITERATUR

  • 1 Aoki N, Masaaki M, Sakata Y, Yoshida N, Matsuda M. Abnormal Plasminogen. A hereditary molecular abnormality found in a patient with recurrent thrombosis. J. Clin. Invest. 61: 1186 1978;
    PubMedGoogle Scholar
  • 2 Aoki N, Saito H, Kamiya T, Koie K, Sakata Y, Kobakura M. Congenital deficiency of α2-antiplasmin inhibitor associated with severe hemorrhagic tendency. J. Clin. Invest 63: 877 1979;
    CrossrefPubMedGoogle Scholar
  • 3 Bingenheimer C, Gramse M, Egbring R, Havemann K. Fibrinogen degradation by two neutral granulocyte proteinases. Influence of calcium on the generation of fibrinogen degradation products with anticlotting properties. Hoppe-Seyler’s Z. physiol. Chem. 362: 853 1981;
    PubMedGoogle Scholar
  • 4 Brommer E.J.P, Brakman P, Haverkate E, Kluft C, Traas D, Wijngaards G. Progress in fibrinolysis. In: Poller L. (Ed.) Recent Advances in Blood Coagulation. S. 125. Churchill Livingstone; Edinburgh, London, Melbourne, New York: 1981
    Google Scholar
  • 5 Collen D. On the regulation and control of fibrinolysis. Haemostasis and Thrombosis 43: 11 1980;
    PubMedGoogle Scholar
  • 6 Crabtree G.R, Kant J.A. Organization of the rat γ-fibrinogen gene: Alternative mRNA splice patterns produce the γA and γB (γ’) chains of fibrinogen. Cell 31: 159 1982;
    CrossrefPubMedGoogle Scholar
  • 7 Doolittle R.E. Structural aspects of the fibrinogen to fibrin conversion. Adv. Protein Chem. 27: 1 1973;
    CrossrefPubMedGoogle Scholar
  • 8 Doolittle R.E. Fibrinogen and Fibrin. Scient. Am. 245: 92 1981;
    PubMedGoogle Scholar
  • 9 Folk J.E, Finlayson J.S. The ε-(γ-glutamyl) lysine crosslink and the catalytic role of transglutaminases. Adv. Protein Chem. 31: 2 1977;
    PubMedGoogle Scholar
  • 10 Haverkate E. Lysis of crosslinked and non-cross-linked purified fibrin. Thromb. Diath. Haemorrh. (Stuttgart) 34: 584 1975;
    PubMedGoogle Scholar
  • 11 Haverkate E, Brakman P. Fibrin plate assay. In: Davidson J.F, Samama M.M, Desnoyers P.C. (Eds.) Progress in Chemical Fibrinolysis and Thrombolysis Vol.1, S. 151. Raven Press; New York: 1975
    Google Scholar
  • 12 Haverkate F, Timan G. Preparation of highly purified bovine fibrin plates. In: Davidson J.E, Samama M.M, Desnoyers P.C. (Eds.) Progress in Chemical Fibrinolysis and Thrombolysis Vol.2, S.67. Raven Press; New York: 1976
    Google Scholar
  • 13 Haverkate F, Timan G. Protective effect of calcium in the plasmin degradation of fibrinogen and fibrin fragment D. Thrombos. Res. 10: 803 1977;
    CrossrefPubMedGoogle Scholar
  • 14 Haverkate E, Koopman J, Kluft C, Boschman T.A.C, Jansen J. (in Vorbereitung).
    PubMed
  • 15 Henschen A. Fibrinogen-Blutgerinnungsfaktor I. Biochemische Aspekte. Hämostaseologie 1: 30 1981;
    PubMedGoogle Scholar
  • 16 Henschen A, Lottspeich F, Kehl M. Structure-Function-Evolution Relationship in Fibrinogen. In: Henschen A, Graeff H, Lottspeich F. (Ed.) Fibrinogen, Recent Biochemical and Medical Aspects S. 67. de Gruyter; Berlin, New York: 1982
    Google Scholar
  • 17 Izaki S, Kitáguchi H. Calcium dependent and independent release of plasminogen activator from the vascular wall. Thrombos. Res. 10: 765 1977;
    CrossrefPubMedGoogle Scholar
  • 18 Kluft C. Plasminogen proactivators and activators in human plasma: factor XII-dependent fibrinolysis. In: Peeters H. (Ed.) Protides of the Biological Fluids. S. 375. Pergamon Press; Brüssel: 1980
    Google Scholar
  • 19 Kluft C, Vellenga E, Brommer E.J.P, Wijngaards G. A familial hemorrhagic diathesis in a dutch family: an inherited deficiency of α2-antiplas-min. Blood 59: 1169 1982;
    PubMedGoogle Scholar
  • 20 Koopman J, Haverkate F. Formation of fibrin degradation products from a non-anticoagulated whole blood clot. In: Haverkate F, Nieuwen-huizen W, Henschen A, Straub P.W. (Eds.) Fibrinogen, Structure, Functional Aspects, Metabolism. S.255. de Gruyter; Berlin, New York: 1983
    Google Scholar
  • 21 Lawrie J.S, Kemp G. Evidence for the presence of a calcium ion binding site within fibrinogen fragment D. Biochem. Soc. Trans. 6: 769 1978;
    CrossrefPubMedGoogle Scholar
  • 22 Lindsey G.G, Brown G, Purves L.R. Calcium binding to human fibrinogen-localisation of two calcium specific sites. Thrombosis Res. 13: 345 1978;
    CrossrefPubMedGoogle Scholar
  • 23 Lorand L, Jacobsen A. Studies of the polymerization of fibrin. The role of the globulin fibrin stabilizing factor. J. Biol. Chem. 230: 420 1958;
    PubMedGoogle Scholar
  • 24 Marder V.J, Budzynski A.Z. The structure of the fibrinogen degradation products. In: Spaet T.H. (Ed.) Progress in Haemostasis and Thrombosis, Vol. 2, S. 141. Grune & Stratton; London, New York: 1974
    Google Scholar
  • 25 Marguerie G, Chagniel G, Suscillon M. The binding of calcium to bovine fibrinogen. Biochem. Biophys. Acta 490: 94 1977;
    CrossrefPubMedGoogle Scholar
  • 26 Miles L.A, Plow E.F, Donnelly K.J, Howgie C, Griffin J.H. A bleeding disorder due to deficiency of α2-antiplasmin. Blood 59: 1246 1982;
    PubMedGoogle Scholar
  • 27 Nieuwenhuizen W, Vermond A, Nooijen W.J, Haverkate F. Calcium binding properties of human fibrin(ogen) and degradation products. FEBS Letters 98: 257 1979;
    CrossrefPubMedGoogle Scholar
  • 28 Nieuwenhuizen W, Emeis J.J, Vermond A, Korver P, van der Heide D. Studies on the catabo-lism and distribution of fibrinogen in rats. Application of the iodogen® labelling technique. Biochem. Biophys. Res. Commun. 97: 49 1980;
    CrossrefPubMedGoogle Scholar
  • 29 Nieuwenhuizen W, Vermond A, Haverkate F. Factors influencing the structure of terminal plas-min degradation products of human fibrinogen and fibrin. Biochim. Biophys. Acta 667: 321 1981; a
    CrossrefPubMedGoogle Scholar
  • 30 Nieuwenhuizen W, Ruyven-Vermeer I.A.M, Nooijen W.J, Vermond W, Haverkate F. Recalculation of calcium-binding properties of human and rat fibrin(ogen) and their degradation products. Thrombosis Res. 22: 653 1981; b
    CrossrefPubMedGoogle Scholar
  • 31 Nieuwenhuizen W, Voskuilen M, Vermond A, Haverkate F. A fibrinogen fragment D (D intermediate) with calcium binding but without anticlot-ting properties. Biochim. Biophys. Acta 707: 190 1982;
    CrossrefPubMedGoogle Scholar
  • 32 Purves L.R, Lindsey G.G. Role of calcium in the structure and interactions of fibrinogen. S. Afr. J. Sci. 74: 202 1978;
    PubMedGoogle Scholar
  • 33 Rampling M.W. Factor XIII crosslinking and rate of fibrinolysis induced by streptokinase and urokinase. Thrombos. Res. 12: 287 1978;
    CrossrefPubMedGoogle Scholar
  • 34 Rijken D.C, Wijngaards G, Zaal-de Jong M, Welbergen J. Purification and partial characterization of plasminogen activator from human uterine tissue. Biochim. Biophys. Acta 580: 140 1979;
    CrossrefPubMedGoogle Scholar
  • 35 Rijken D.C, Collen D. Purification and characterization of the plasminogen activator secreted by human melanoma cells in culture. J. Biol. Chem. 256: 7035 1981;
    PubMedGoogle Scholar
  • 36 Ruijven-Vermeer IAMvan, Nieuwenhuizen W. Purification of rat fibrinogen and its constituent chains. Biochem. J. 769: 653 1978;
    PubMedGoogle Scholar
  • 37 Rupp C, Kuyas C, Häberli A, Furlan M, Perret B.A, Beck E.A. Fibrinogen Bern I: A hereditary fibrinogen variant with defective conformational stabilization by calcium ions. In: Henschen A, Graeff H, Lottspeich F. (Eds.) Fibrinogen, Recent Biochemical and Medical Aspects S. 167. de Gruyter; Berlin, New York: 1982
    Google Scholar
  • 38 Sakata Y, Aoki N. Crosslinking of α2-antiplas-min inhibitor to fibrin by fibrin-stabilizing factor. J. Clin. Invest. 65: 290 1980;
    CrossrefPubMedGoogle Scholar
  • 39 Sakata Y, Aoki N. Significance of crosslinking of α2-plasmin inhibitor to fibrin in inhibition of fibrinolysis and in hemostasis. J. Clin. Invest. 69: 536 1982;
    CrossrefPubMedGoogle Scholar
  • 40 Soria J, Soria C, Bertrand O, Lefur M.A, Drouet L, Baudouy Y, Dupuy E, Tobelem G, Caen J. Congenital abnormal plasminogen: Plasminogen Paris I-Relationship with thrombosis. Haemostasis 11(Suppl.1): 1 1982; a
    PubMedGoogle Scholar
  • 41 Soria J, Soria C, Samama M, Henschen A, Southan C. Detection of fibrinogen abnormality in dysfibrinogenemia. In: Henschen A, Graeff H, Lottspeich F. (Eds.) Fibrinogen, Recent Biochemical and Medical Aspects. S. 129. de Gruyter; Berlin, New York: 1982. b
    Google Scholar
  • 42 Taylor F.B, Carroll R.C, Gerrard J, Esmon C.T, Radcliffe R.D. Lysis of clots prepared from whole blood and plasma. Federation Proc. 40: 2092 1981;
    PubMedGoogle Scholar
  • 43 Tillet W.S, Garner R.L. The fibrinolytic activity of hemolytic streptococci. J. Exp. Med. 58: 485 1933;
    CrossrefPubMedGoogle Scholar
  • 44 Wohl R.C, Summaria L, Chediak J, Rosen-feld S, Robbins K.C. Human Plasminogen Variant Chicago III. Thrombosis Haemostasis (Stuttgart) 48: 146 1982;
    PubMedGoogle Scholar
  • 45 Yoshioka A, Kamitsuji H, Takase T, lida Y, Tsukada S, Mikami S, Fukui H. Congenital deficiency of α2-Plasmin Inhibitor in three sisters. Haemostasis 11: 176 1982;
    PubMedGoogle Scholar